Product Details

Verdia is a sterile injectable formulation that meets British Pharmacopoeia (BP) standards. Specifically, it delivers Diazepam at 10mg per 2mL for use through the intramuscular (I.M.) or slow intravenous (I.V.) route. As a result, it offers a long-acting benzodiazepine for sedation, anxiolysis, and anticonvulsant management in a range of clinical settings.

The injection contains:

• Diazepam BP (10mg per 2mL) – A long-acting benzodiazepine that enhances GABA-A receptor activity in the central nervous system. Consequently, it produces sedation, anxiolysis, skeletal muscle relaxation, and anticonvulsant effects, with a comparatively extended duration of action.

Physicians use Verdia for the management of acute anxiety states, status epilepticus and other convulsive disorders, skeletal muscle spasm, and as premedication before surgical or endoscopic procedures. In addition, its dual-route (I.M./slow I.V.) formulation allows flexible administration based on clinical urgency. Because of this profile, Verdia suits hospitals, ICUs, and emergency departments where prompt sedative or anticonvulsant intervention is required.

Key Features:

• Overall, this BP-compliant formulation guarantees pharmaceutical-grade purity
• Additionally, the dual-route (I.M./slow I.V.) formulation offers flexible clinical use
• Furthermore, each ampoule delivers precise, validated dosage accuracy at 10mg/2mL
• Notably, rigorous purity and sterility testing backs every stage of manufacturing
• Beyond that, light-protected ampoule packaging preserves product stability during storage
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, ICUs, and emergency care units